Valuation: ProPhase Labs, Inc.

Market Cap 1.28M 1.12M 1.03M 966K 1.81M 120M 1.85M 12.4M 4.8M 59.53M 4.79M 4.69M 206M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 9.8M 8.6M 7.92M 7.42M 13.91M 925M 14.2M 95.24M 36.85M 457M 36.82M 36.01M 1.59B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
91.93%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day+9.77%
1 week+32.28%
Current month+0.10%
1 month+16.69%
3 months+38.89%
6 months-80.77%
Current year-77.65%
1 week 0.08
Extreme 0.075
0.12
1 month 0.07
Extreme 0.0723
0.15
Current year 0.07
Extreme 0.068
0.47
1 year 0.07
Extreme 0.068
6.66
3 years 0.07
Extreme 0.068
75.9
5 years 0.07
Extreme 0.068
152.5
10 years 0.07
Extreme 0.068
160.4
Manager TitleAgeSince
Chief Executive Officer 67 19/06/2009
Director of Finance/CFO 66 06/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 19/06/2009
Director/Board Member 70 01/06/2009
Director/Board Member 56 20/06/2025
Date Insider Type Main position Quantity % Market Cap.
09/09/25Free

Chief Executive Officer

500,000 1.2036%
17/02/25Free

Chief Operating Officer

500,000 1.6737%
14/02/25Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
+9.77%+32.28%-97.08%-99.86% 1.28M
+0.45%+14.47%+55.74%+425.40% 37.34B
+1.93%+6.70%+5.64%+14.94% 21.84B
-0.78%+2.92%-21.91%-41.22% 7.04B
+1.22%+8.93%+4.63%+85.41% 4.72B
+1.76%+1.58%+22.09%+60.13% 2.99B
+1.67%+25.98%-22.07%+1,097.60% 2.04B
-4.74%+3.56%+29.74%-27.79% 1.78B
+3.20%+26.52%+97.91%-12.69% 1.79B
-6.73%-9.88%-22.08%-69.93% 1.62B
Average +0.90%+7.96%+5.26%+143.20% 8.12B
Weighted average by Cap. +1.27%+8.55%+28.16%+228.64%

Financials

2024 2025
Net sales 6.77M 5.94M 5.47M 5.12M 9.61M 639M 9.8M 65.76M 25.45M 316M 25.42M 24.87M 1.09B 4.34M 3.81M 3.51M 3.29M 6.16M 410M 6.29M 42.21M 16.33M 203M 16.32M 15.96M 702M
Net income -53.36M -46.79M -43.13M -40.38M -75.71M -5.03B -77.29M -518M -201M -2.49B -200M -196M -8.63B -14.74M -12.93M -11.92M -11.16M -20.92M -1.39B -21.35M -143M -55.42M -687M -55.36M -54.15M -2.38B
Net Debt 23.9M 20.95M 19.31M 18.08M 33.9M 2.25B 34.61M 232M 89.82M 1.11B 89.73M 87.77M 3.86B 8.53M 7.48M 6.89M 6.45M 12.1M 804M 12.35M 82.84M 32.06M 398M 32.02M 31.32M 1.38B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
26/06/26 $0.1000 +9.77% 23,213
25/06/26 $0.0911 -4.61% 5,796
24/06/26 $0.0955 -13.18% 8,184
23/06/26 $0.1100 +45.50% 164,727
22/06/26 $0.0756 +0.80% 4,041

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock